Mutations which disrupt the regulation or expression level of the c-myc gene are among the most common found in human and animal cancers (reviewed in ref. Cole, 1986; Henriksson and Luscher, 1996; Marcu et al., 1992) . Ectopic expression studies de®ne numerous biological activities of the c-myc gene, including transformation, immortalization, blockage of cell dierentiation and induction of apoptosis (Askew et al., 1991; Cole, 1986; Evan and Littlewood, 1993; Freytag et al., 1990; Henriksson and Luscher, 1996; Marcu et al., 1992) . Furthermore, c-myc is required for ecient progression through the cell cycle (Goruppi et al., 1994; Prochownik et al., 1988; Yokoyama and Imamoto, 1987) , although recent studies indicate that it is not absolutely essential (Mateyak et al., 1997) . This fascinating array of biological activities makes the cmyc gene one of the most intriguing oncogenes and presents the challenging question of how a single gene can manifest so many dierent eects. The c-Myc protein exhibits sequence-speci®c DNA binding when dimerized with its partner Max, and DNA binding is mediated through the basic region, which recognizes the core sequence CACGTG (Berberich et al., 1992; Blackwell et al., 1993; Blackwood and Eisenman, 1991; , but exhibits somewhat higher anity for the more extended sequence ACCACGTGGT (Berberich et al., 1992; Blackwell et al., 1993; Halazonetis and Kandil, 1991) . There are three closely related Myc family proteins (c-Myc, N-Myc and L-Myc) , each with documented oncogenic potential (Birrer et al., 1988; Schwab et al., 1985; Yancopoulos et al., 1985) and similar DNA binding properties (Mukherjee et al., 1992) . For simplicity, we will use the term Myc to refer to all three proteins, but delineate any distinct activities where they apply. The goal of this review is to discuss Myc as a transcriptional activator and critically evaluate the evidence for the transactivation of speci®c target genes as direct downstream eectors. Since excellent comprehensive reviews on Myc have been published recently (Facchini and Penn, 1998; Henriksson and Luscher, 1996) , we will focus on the latest observations that oer mechanistic insight into transactivation and oncogenic transformation.
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Functional domains and Myc transactivation
Like most transcription factors, the Myc protein has two major domains. The C-terminal 90 amino acids are required for dimerization with Max and sequencespeci®c DNA binding (Blackwood and Eisenman, 1991; . Disruption of this domain destroys all biological activity (Stone et al., 1987) , indicating that DNA binding is essential for function. The second domain encompasses the remaining three-fourths of the Myc protein and can be broadly de®ned as involved in`transactivation' (Kato et al., 1990) . Transactivation of cellular promoters by Myc is quite low in transient assays, usually about 3 ± 5 fold (see Table 1 ). Reiteration of Myc/Max consensus binding sites in an arti®cial reporter construct can yield up to eightfold transactivation (Amin et al., 1993; Gu et al., 1993; Kretzner et al., 1992) , whereas fusion of the Myc N-terminus to the GAL4 DNA binding domain has been reported to yield 20 ± 200-fold transactivation in various studies (Brough et al., 1995; Kato et al., 1990; Resar et al., 1993) . The cellular factors that contribute to this transient transactivation remain unknown, although a direct interaction with the TATA binding protein has been reported (Hateboer et al., 1993; Maheswaran et al., 1994) . The c-Myc N-terminus has short`acidic', proline-rich' and`glutamine-rich' clusters similar to those associated with some transactivation domains (Kato et al., 1990) , but the role of these regions in biological activity has not been thoroughly tested. The glutamine-rich region of c-Myc is dispensable for oncogenic activity (Stone et al., 1987) . In addition, the Myc N-terminus can`squelch' transactivation by the herpes virus transactivator VP16 (Resar et al., 1993) , suggesting that the two proteins compete for common cellular factors in transient assays. GAL4 fusion proteins with the L-Myc N-terminus have reduced transactivation compared to fusions with cMyc, which correlates with the weaker oncogenic potential of L-Myc in most assays (Barrett et al., 1992) . Speci®c regions responsible for these dierences have not been mapped, nor has there been a comparison of cellular promoter transactivation by cMyc and L-Myc themselves.
Like the DNA binding domain, early reports indicated that the N-terminal transactivation domain is also required for Myc's biological activities. Myc proteins containing deletions within the N-terminus have reduced abilities to cooperate with the ras oncogene, to induce foci in a rat ®broblast line, and to block the dierentiation of adipocytes (Stone et al., 1987; Sarid et al., 1987; Freytag et al., 1990) . However, these deletions with arbitrary boundaries appear to contrast with a naturally occurring variant of c-Myc called MycS. The MycS protein originates from translation initiation at either of two methionines at amino acids 100 ± 110 in relation to the M1 position of the most abundant Myc2 protein, which means that MycS retains approximately 260 amino acids Nterminal to the DNA binding domain (Spotts et al., 1997) . Even though MycS is devoid of all transactivation activity assayed with reporter constructs, ectopic expression of MycS can induce anchorage-independent growth and apoptosis as well as rescue the cell cycle delay of Myc-de®cient ®broblasts (Xiao et al., 1998) . Conversely, replacing the c-Myc N-terminus with the potent transactivation domain from the herpesvirus VP16 protein fails to reconstitute an oncogenic function (Brough et al., 1995) . Thus, transactivation by the Myc N-terminus (as de®ned by transient reporter assays) is neither necessary nor sucient in many biological assays. On the other hand, it remains entirely possible that the transactivation of speci®c cellular promoters is required for Myc function and that the apparent dichotomy is only a consequence of the inability of transient reporter assays to recapitulate the regulation of chromosomal targets. Alternately, the biological functions of Myc may be linked to gene repression rather than activation, although the mechanism of repression and its direct association with Myc remain unclear (Claassen and Hann, 1999) .
TRRAP links Myc transactivation to chromatin remodeling and histone acetylation
The Myc N-terminus contains several discrete blocks of amino acids which have been conserved in all Myc family proteins throughout evolution (Cole, 1986; Henriksson and Luscher, 1996) , referred to as Myc homology boxes. Among the three major conserved regions of the N-terminus, the most critical for oncogenic transformation is Myc box II (MbII) (Stone et al., 1987) , which is centered around amino acid 135 in human c-Myc. Small deletions or single missense mutations in MbII are sucient to eliminate virtually all Myc biological activity, including oncogenic activity, apoptosis and blocking dierentiation (Askew et al., 1991; Brough et al., 1995; Evan et al., 1992; Freytag et al., 1990; Li et al., 1994; MacGregor et al., 1996) . Interestingly, MbII mutants have unaltered or even enhanced transactivation in most reported promoter fusion constructs with one exception (Bello-Fernandez et al., 1993; Brough et al., 1995; Desbarats et al., 1995) . The MbII domain has recently been shown to facilitate Myc binding to a novel large nuclear cofactor called TRRAP (TRansactivation/tRansformation-domain Associated Protein) . TRRAP is a 3830 amino acid protein with limited homology to the PI3 kinase/ATM family, although TRRAP lacks the kinase catalytic residues present in other members of the family. TRRAP binding to the N-terminus is directly correlated with Myc oncogenic activity, since deletions or mutations in Myc that disrupt TRRAP binding are transformation-defective and the weakly transforming L-Myc protein exhibits poor TRRAP binding. Furthermore, the disruption of endogenous TRRAP pools using antisense and dominant inhibitory constructs severely impairs Myc-mediated oncogenic transformation. These data imply that the recruitment of TRRAP to cellular promoters is essential for Myc-mediated oncogenic transformation.
The identi®cation of TRRAP as an essential cofactor provided an important mechanistic insight into the function of the Myc N-terminal domain when TRRAP was found to be part of the SAGA complex (Saleh et al., 1998) . SAGA (SPT/ADA/GCN5/Acetyltransferase) is a 1.8 MDa complex containing approximately 20 proteins which have been implicated in transcriptional regulation, primarily through genetic screens in yeast (Grant et al., 1997) . However, several recent studies have demonstrated that in addition to TRRAP, many other components of the SAGA complex are also highly conserved from yeast to humans (Martinez et al., 1998; Ogryzko et al., 1998; Smith et al., 1998a) . Among the many proteins contained in SAGA, the only one with a clearly de®ned biochemical function is the histone acetyltransferase GCN5 (Georgakopoulos and Thireos, 1992; Marcus et al., 1994; Wang et al., 1997) . Histone acetylation by transcription cofactors has frequently been associated with gene activation (Grant et al., 1998) , making this an attractive mechanism for Mycmediated transactivation. This model is appealing since A general model of Myc-mediated histone acetylation as the basis of oncogenic transformation raises a number of important questions that must be addressed in the future. First, the TRRAP ortholog in S. cerevisiae (TRA1p) is essential for viability whereas the GCN5p protein is non-essential (Marcus et al., 1994; Saleh et al., 1998) . This observation raises the possibility that some other component of the SAGA complex is a critical mediator of Mycdependent gene regulation. One possibility is that TRRAP is associated with another histone acetyltransferase such as the mammalian ortholog of the essential ESA1p protein (called TIP60 in humans) (Kamine et al., 1996; Smith et al., 1998b) . However, preliminary experiments fail to show an interaction between Myc and TIP60 (S McMahon, unpublished results). Alternately, TRRAP itself may have a unique gene regulatory function that is not predicted through known protein motifs. A second major question is which, if any, Myc target genes are dependent on the MbII domain and hence presumably on TRRAP and histone acetylation. In most assays, it is repression by Myc that is dependent on MbII, not transactivation (Li et al., 1994; Penn et al., 1990) . However, repression is not consistent with the expected role of histone acetylation in opening condensed chromatin. The latter question will be discussed in more detail below. Finally, there are likely to be other cofactors recruited by Myc that contribute gene regulatory functions. For example, the MycS protein does not bind to TRRAP and cannot cooperate with H-ras to transform primary rodent cells . This suggests that MycS may interact with other cofactors to mediate cell cycle progression, anchorage-independent growth and apoptosis. The identi®cation of additional Myc cofactors may oer new mechanistic insights into oncogenic transformation. Other proteins reported to interact with Myc are discussed elsewhere in this issue (B LuÈ scher and colleagues).
What are Myc's target genes?
The single biggest impediment to understanding the function of the c-Myc protein is the lack of a comprehensive set of Myc target genes. The diculty stems in part from the fact that myc was ®rst identi®ed genetically, i.e. as the oncogenic sequence within dierent avian viruses and as a site of chromosomal lesions in diverse tumors (reviewed in Cole, 1986) . This contrasts with the majority of transcription factors, which have in general been identi®ed through their binding to key regulatory elements in speci®c promoters. Myc DNA binding activity is virtually undetectable in most cells, so in the absence of the genetic and oncogenic links the protein would have gone undetected by most conventional approaches to transcriptional regulation.
Numerous studies have attempted to identify the targets of the Myc oncogene, mainly using dierential or subtractive hybridization, or guessing based on expression pattern. In addition to the speci®c techniques utilized, the search for c-Myc targets is heavily in¯uenced by underlying assumptions inherent in any screen. Is Myc an activator or repressor? Will the expression of the target gene be higher in Myc transformed cells than in normal growing cells or simply expressed at the same level in both cell types? A compilation of all proposed Myc targets and the means of identi®cation has been presented in recent comprehensive reviews (Dang, 1999; Facchini and Penn, 1998; Grandori and Eisenman, 1997) . In this review, we will focus on only the proposed targets ( It is important to note an often overlooked ®nding from innumerable studies of proposed Myc targets. Ectopic expression of Myc rarely if ever leads to any net upregulation of proposed target genes compared to controls with the expression vector alone, as long as the culture conditions are not biased to favor the growth of only the Myc-expressing cells. An example of the latter are cells deprived of growth factors, where ectopic Myc promotes factor-independent growth. Under these circumstances, it becomes dicult to distinguish direct Myc-dependent gene regulation from the indirect consequences of growth. For even the best candidate targets, the level of endogenous Myc protein is not rate-limiting for transcriptional regulation. Some exceptions to this general ®nding are discussed below.
Before discussing the potential contribution of proposed Myc target genes to growth and oncogenesis, it is useful to review the dierent assays that have been used to implicate individual genes in Mycdependent regulation. The strengths and weaknesses of each assay for assigning a direct regulatory link between Myc and target genes are noted.
(A) Misregulation of candidate target genes in Mycde®cient ®broblasts. An extremely powerful new tool to evaluate candidate Myc target genes is a Rat1 cell line rendered completely Myc-de®cient by homologous recombination (Mateyak et al., 1997) . These Myc null cells do not express c-Myc, N-Myc or L-Myc and, although they continue to grow, they have a dramatically extended cell cycle time that is nearly three times longer than their wild type parent. In these cells, direct Myc transactivation targets are expected to exhibit reduced expression, and Myc-dependent regulation can be studied in both log phase and after (Sirito et al., 1994) ) has discouraged its use. The importance of demonstrating in vivo binding to a potential regulatory site is underscored by a recent unanticipated ®nding in studies of the E2F transcription factor family, which shares the complexities of the Myc family. Transient assays suggested that an E2F binding site in the B-myb promoter was the target of E2F-mediated transactivation (Zwicker et al., 1996) (Lutz et al., 1996) , although unlike MycER induction must allow cellular protein synthesis. (E) Transient expression of Myc with candidate target promoters. The dissection of regulatory elements within promoters continues to require the analysis of promoter fusions with reporter constructs. However, since the location of Myc/Max binding sites may in¯uence inducibility (Gaubatz et al., 1994; Boyd et al., 1998) 
The cad gene exhibits a unique Myc-dependent regulation
The Myc loss-of-function analysis in Rat1 ®broblasts provided the surprising ®nding that virtually all of the proposed Myc transactivation targets were unaected by the Myc-de®ciency in growing cells (Bush et al., 1998) . Therefore, the unaected genes must not contribute to the stable slow growth phenotype caused by the Myc knockout. Only the cad gene was consistently downregulated in proliferating Myc-deficient cells, and even this downregulaton was quite modest (*threefold). The absence of Myc also had the most severe aect on the cad gene during serum stimulation (*eightfold). Reconstitution of Myc into the null cells restores cad expression to a level at or above that found in parental cells, con®rming that the downregulation was indeed Myc-dependent. Furthermore, the cad promoter has been demonstrated to interact with Myc and Max in vivo by crosslinking (Boyd and Farnham, 1997; Boyd et al., 1998) . Thus, the cad gene appears to be uniquely dependent on Myc compared to other proposed targets.
It is useful to consider several features of the cad promoter that might make it more dependent on endogenous Myc than with other genes. First, cad is the only Myc target without a TATA element in the promoter (Kollmar et al., 1994) . Second, the Myc/Max consensus binding site shown to contribute to gene regulation falls at +65 from the major mRNA initiation site (Miltenberger et al., 1995) . This site is closer to the transcription start site than those mapped in other promoters, although it conforms to the frequent ®nding that the Myc/Max binding sites are within transcribed regions rather than in the 5'¯anking sequences. Third, the Myc/Max consensus binding site is well conserved in both sequence and location in dierent mammals where it has been mapped (Boyd and Farnham, 1997; Boyd et al., 1998) . Fourth, the cad Myc-level required for activation a promoter contains Sp1 sites that contribute to basal expression and also may contribute cooperatively to cad regulation by Myc (Kollmar et al., 1994) . No other proposed target promoters have these speci®c features, although the relative importance of each to Mycdependent regulation remains unresolved. It will be important to determine if cad is dependent on TRRAP and the SAGA chromatin remodeling complex or on other Myc cofactors. Preliminary experiments suggest that cad expression is not dependent on MbII in log phase cells (M Cole, unpublished data) .
It is interesting to note that the time course of cad induction does not directly parallel c-Myc protein expression. The cad expression peaks at 8 ± 12 h after serum stimulation, whereas Myc protein levels peak at 3 h (Bush et al., 1998) . However, c-Myc continues to be synthesized and levels remain high during the time of peak cad induction (Mateyak et al., 1997) , so it is possible that the transcriptional activity of c-Myc may be dierentially regulated at distinct points in G 1 (Colman and Ostrowski, 1996; Lutterbach and Hann, 1994) . Alternately, some cofactor that parallels cad induction may synergize with Myc to activate the promoter.
Target genes aected by Myc during growth stimulation and growth suppression Withdrawal of essential growth factors suppresses proliferation and leads to the downregulation of growth-regulated genes, including c-myc and most proposed Myc targets. Sustained or inducible Myc expression, including the activation of MycER, promotes cell growth during growth factor deprivation, b Figure 1 Models of gene-speci®c and global transcriptional regulation by Myc family proteins. (a) Genes speci®cally regulated by Myc proteins have been divided into three classes. Most of the currently known Myc targets fall into Class I, where eects of Myc are seen only following experimental manipulation of Myc protein levels. These genes are unaected by the absence of Myc in knockout cells, and can therefore not be responsible for the profound proliferative defects seen in these cells. Evidence suggests that Myc-dependent regulation of Class I genes is observed only when Myc protein concentrations are raised to arti®cially high levels, such as following transient transfection or induction of MycER. It is possible that in certain tumor cells, Myc levels are similarly raised to very high levels, bringing these genes under the control Myc. However, in most cases upregulation in Myc-induced tumor cells has not been documented experimentally. The only known gene belonging to Class II is cad, which is strongly downregulated in cells lacking Myc. Furthermore, cad levels are restored in knockout cells which have been rescued by re-introduction of Myc and Myc proteins have been crosslinked to the cad gene in vivo. However, it is only the as yet unknown targets which comprise Class III which are dependent on the biologically critical N-terminal MbII domain of the Myc protein. These hypothetical Class III targets may also be dependent on the MbII-dependent cofactor TRRAP, which links Myc to the large transcriptional regulatory SAGA complex. (b) Myc proteins may exert global aects on gene expression by inducing regional chromatin remodeling in the vicinity of Myc binding sites in the genome. Because Myc binding sites occur at a high frequency (approximately every 4000 bp) in the genome, this mechanism may be dicult to detect with standard assays of gene expression. Like gene-speci®c regulation, this mechanism may rely on the ability of Myc to recruit TRRAP and the associated SAGA complex. It is important to note that the gene-speci®c and global mechanisms of Myc-dependent transcriptional regulation presented here are not mutually exclusive sometimes making cells growth factor-independent. It has always been dicult to separate the direct eect of Myc on target gene expression from indirect gene activation as a consequence of cell growth. MycER activation oers one solution to this problem, since the fusion protein can be activated by hormone in growth factor deprived cells in the presence of cyclohexamide. MycER can activate prothymosin (Eilers et al., 1991) , ODC , LDH-A (Shim et al., 1997) , MrDb (Grandori et al., 1996) and cdc25A (Galaktionov et al., 1996) under these conditions. Quantitation of MrDb induction with the tamoxifen-inducible MycER fusion showed a 1.8-fold increase when normalized to GAPDH expression (Grandori et al., 1996) .
An alternate approach to the problem is to compare growth factor-induced gene expression in Myc null cells with that in their parental line. When normalized to controls, prothymosin, ODC, MrDb and cdc25A exhibit a small reduction (1.5 ± 2-fold) in the initial growth factor induction in Myc null cells, but the RNA levels become equal to the parental line by 24 h (Bush et al., 1998) . The latter observation is consistent with the equal levels of mRNA from these genes in log phase Myc null and wild type cells. The Mycdependent contribution in this assay is similar to that observed with MycER (1.5 ± 2-fold in each case).
Combining the two assays above with promoter mapping that demonstrates functional Myc/Max consensus binding sites suggests that Myc makes a small contribution (1.5 ± 2-fold) to the activation of prothymosin, ODC, MrDb, LDH-A and cdc25A during the early phases of growth factor stimulation. More importantly, these studies make it clear that other factors must account for the majority of the growth factor inducibility of these genes. The Mycdependence of these genes disappears as cells reach a steady state of cell cycle progression, whether at a normal rate in wild type cells or a very slow rate in Myc null cells. For the targets in this group, it is interesting to note that the contribution of Myc to growth factor inducible gene expression peaks at 3 h along with the peak of Myc expression, whereas the more dramatic Myc-dependent regulation of cad peaks later. This observation suggests that transactivation by Myc occurs through a dierent mechanism or through dierent cofactors in the dierent classes of target genes (see Figure 1) .
Proposed Myc targets with insucient characterization to classify
The data in Table 1 shows that many proposed targets have not been characterized as induced by Myc alone or MycER in cell lines, and transient cotransfection assays are insucient to con®rm a regulatory interaction. For example, eIF4E and ECA39 show no misregulation in either log phase or serum stimulated Myc null cells (Bush et al., 1998) . A more comprehensive analysis of these genes should be performed before they are considered bona ®de Myc targets.
Myc/Max binding sites
How does Myc choose speci®c chromosomal sites as targets of transactivation? Myc/Max heterodimers have been shown to bind to both consensus (ACCACGTGGT) and non-consensus sites in vitro, and the binding anity is highest for consensus sites Blackwell et al., 1993; . All of the target genes that exhibit any Myc-dependent regulation in vivo contain E-box elements which conform well to the consensus binding site, and no non-consensus sites which function in chromatin have been identi®ed. Sequence variations introduced into the cad promoter at the +4 and +5 positions (numbered from the dyad center) that have increased anity for USF and decreased anity for Myc/Max are also reduced for growth factor induction (Boyd and Farnham, 1997) . In the limited set of promoters available, there are no common adjacent binding sites for other transcription factors that might contribute combinatorial speci®city.
One factor that will in¯uence the accessibility of potential Myc/Max binding sites in vivo is methylation. The core consensus sequence contains a CpG which is frequently methylated in mammalian cells. Methylation of the consensus site blocks Myc/Max binding, but not binding by USF . The structural basis for this inhibition by CpG methylation is not readily apparent from the existing crystal structure (S Burley, personal comm.). A consequence of this methylation interference is that only non-methylated sites should be available as targets of Myc transactivation during development. How this might in¯uence the dynamics of Myc/Max heterodimer interactions with chromosomes remains to be explored.
General models for Myc-mediated transactivation
Despite recent advances that have identi®ed new Myc cofactors and helped to clarify the contribution of Myc to speci®c target gene transactivation, numerous questions remain to be answered before we can understand how this transcription factor functions in oncogenic transformation. Models that accommodate the existing data are diagrammed in Figure 1 . One model (Figure 1a) is that Myc may function to transactivate 2 ± 3 dierent tiers of target genes, depending on the abundance of Myc in the cell and the activity of other transcription factors. The broadest class may contain genes that are normally regulated as cells transit from a non-growing to growing state. Myc may bind to these genes only when it is expressed at its highest level, and Myc may either supplement transcriptional activation by other transcription factors or enhance the activity of other factors by relieving general chromatin-mediated repression. A second tier of Myc targets is represented by the cad gene, where transcription is dependent on the lower levels of Myc found in log phase cells and on the close proximity of the Myc binding site to the mRNA initiation site. The model also proposes a speculative third tier of Myc targets that are highly dependent on functionally essential domains of Myc, such as MbII. These genes, as yet unidenti®ed, may be more profoundly dependent on Myc in growing cells than cad and these genes may account for the cell cycle defect in the Myc null cells.
The model in Figure 1a casts Myc as a conventional transcription factor with speci®c target genes as downstream eectors. However, it remains possible that the transactivation of select target genes is not at the heart of oncogenic transformation at all. An alternate model (Figure 1b) is that Myc is a global potentiator of chromatin opening or remodeling (perhaps via TRRAP and the SAGA complex), and that Myc provides a subtle but signi®cant enhancement of transcription from hundreds or even thousands of genes simultaneously. A genome-wide increase in transcription would be very dicult to detect due to the lack of a suitable point of normalization. The models in Figure 1 are not mutually exclusive, and it remains possible that Myc may potentiate both genespeci®c and global transcription simultaneously.
Conclusion
There have been major advances in our understanding of Myc-dependent transcriptional activation and target genes in the last year. The derivation of Myc-de®cient cells, in vivo crosslinking, and the identi®cation of new cofactors linking Myc to previously characterized transcriptional regulatory complexes have combined to provide a much clearer picture of the role of Myc in target gene regulation. However, the enigma surrounding the role of Myc in oncogenic transformation remains intact, since no compelling direct target gene that can mediate log phase cell cycle progression has emerged. The recent advances discussed here should make it possible to identify and evaluate new Myc target genes with much greater con®dence in the future.
